Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Accumulated Expenses (2020 - 2023)

Historic Accumulated Expenses for Terns Pharmaceuticals (TERN) over the last 4 years, with Q3 2023 value amounting to $8.1 million.

  • Terns Pharmaceuticals' Accumulated Expenses rose 7058.45% to $8.1 million in Q3 2023 from the same period last year, while for Sep 2023 it was $8.1 million, marking a year-over-year increase of 7058.45%. This contributed to the annual value of $6.2 million for FY2022, which is 3127.4% up from last year.
  • Latest data reveals that Terns Pharmaceuticals reported Accumulated Expenses of $8.1 million as of Q3 2023, which was up 7058.45% from $8.0 million recorded in Q2 2023.
  • In the past 5 years, Terns Pharmaceuticals' Accumulated Expenses ranged from a high of $9.0 million in Q4 2020 and a low of $3.9 million during Q1 2022
  • Moreover, its 4-year median value for Accumulated Expenses was $5.0 million (2021), whereas its average is $6.0 million.
  • In the last 5 years, Terns Pharmaceuticals' Accumulated Expenses tumbled by 4787.92% in 2021 and then skyrocketed by 12451.96% in 2023.
  • Quarter analysis of 4 years shows Terns Pharmaceuticals' Accumulated Expenses stood at $9.0 million in 2020, then tumbled by 47.88% to $4.7 million in 2021, then surged by 31.27% to $6.2 million in 2022, then skyrocketed by 30.72% to $8.1 million in 2023.
  • Its Accumulated Expenses stands at $8.1 million for Q3 2023, versus $8.0 million for Q2 2023 and $8.8 million for Q1 2023.